Position
Fidelity in Aclaris Therapeutics, Inc.
Back to the book · All holders of ACRS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $271.6K$3.75 → $5.29
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 45.8K | $137.9K | — | — | — | 0.0% |
| Q1 2026 | 176.4K | $661.3K | $3.75 | $33.9K | $489.5K | 0.0% |
| Q2 2026 | 313.9K | $1.66M | $5.29 | $271.6K | $727.4K | 0.0% |